

PREVENTEST™ Cancer Risk Analysis

ADVANCED MOLECULAR DIAGNOSTICS, LLC





136 SUMMIT AVE • MONTVALE, NJ 07645 • 🖀 (201) 825-0186 • ☐ (201) 825-0191 • ☐ Info@GenelDLab.com • www.GenelDLab.com **ORDERING PHYSICIAN** SEND RESULTS TO (IF OTHER THAN ORDERING PHYSICIAN) NAME (LAST, FIRST, DEGREE) NPI# NAME (LAST, FIRST, DEGREE) NPI# ADDRESS STATE 7IP ADDRESS STATE CITY 7IP OFFICE PHONE FAX **FMAII** OFFICE PHONE FAX FMAII PATIENT NAME (LAST, FIRST, INITIAL) ☐ FEMALE ☐ MALE BIRTH DATE (MM/DD/YYYY) BEST TIME TO CALL (IF NEEDED) PATIENT INFORMATION ADDRESS CITY STATE CAN WE LEAVE A DETAILED MESSAGE AT THIS NUMBER? FOR INSURANCE COVERAGE) ☐ YES □ NO □ CAUCASIAN □ DUTCH □ SWEDISH □ HUNGARIAN □ ICELANDIC □ AFRICAN/AMERICAN □ MIDDLE EASTERN □ ADOPTED □ ASHKENAZI JEWISH **ANCESTRY** - CHECK ALL THAT APPLY □ LATIN AMERICAN/CARIBBEAN □ ASIAN □ NATIVE AMERICAN □ OTHER PLEASE INCLUDE ALL RELEVANT MEDICAL RECORDS TO SUPPORT THE INFORMATION BELOW PERSONAL HISTORY OF CANCER ☐ PATIENT HAS A PERSONAL HISTORY OF CANCER CANCER TYPE(S) DX AGE(S) PATIENT FAMILY HISTORY OF CANCER - PLEASE INCLUDE ALL RELEVANT MEDICAL RECORDS TO SUPPORT THE INFORMATION BELOW Paternal Dx age Relation to Patient Maternal Relation to Patient Maternal Cancer/Polyp Type Paternal Cancer/Polyp Type Dx age • For Breast Cancer Patients note if Triple Negative (ER-, PR-, HER2-), Invasive, DCIS, Bilateral, Premenopausal • For Prostate Cancer Patients include Gleason Score ☐ IS PATIENT CURRENTLY BEING TREATED FOR CANCER (FOR PATIENTS WITH A PERSONAL HISTORY OF CANCER) GS denotes gleason score MP denotes multiple primaries PREMM₅ ☐ COLON POLYPS (K63.5) # OF POLYPS ☐ BONE MARROW TRANSPLANT RECIPIENT 3x- denotes triple negative HR denotes high-risk ethnicity MT denotes metachronous tumor ST denotes synchronous tumor ☐ KNOWN FAMILIAL MUTATION: GENE MUTATION □ PREVENTEST Hereditary Cancer Risk Analysis - APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, ELAC2, EPCAM, HOXB13, MLH1, MRE11A, MSH2, MSH6, **TFST** MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL4, RET, RINT1, SMAD4, STK11, TP53 **REQUESTED** ☐ CUSTOM (specify genes from PrevenTest panel Appropriate Common Diagnosis COMPATIBLE ICD-10 - Insurance coverage is not required for genetic testing. The diagnostic code (ICD-10) information provided herein is for insurance information purposes only and does not guarantee insurance coverage for any genetic test, nor is it intended to be a definitive list of diagnosis codes that may be applicable for any individual patient. The testing laboratory will pursue reimbursement directly from the patient should the patient's insurance carrier deny coverage. FAMILY HISTORY OF CANCER AND GENETIC MUTATION ICD-10 CODES DESCRIPTION DESCRIPTION Family history of malignant neoplasm, other specified Z80.3 Family history of malignant neoplasm, breast Z80.8 Z80.59 Family history of malignant neoplasm of other urinary tract organ Z80.41 Family history of malignant neoplasm, ovary Z80.42 Family history of prostate cancer Z84.81 Family history of BRCA or Lynch Syndrome gene mutation Z80.0 Family history of malignant neoplasm- colon or GI cancers Z80.49 Family history of cancer of genital system Z80.9 Family history of malignant neoplasm, unspecified PATIENT PERSONAL HISTORY OF CANCER ICD-10 CODES BREAST CANCER PROSTATE CANCER OTHER CANCERS DESCRIPTION DESCRIPTION ICD10 DESCRIPTION C50.919 Malignant neoplasm, breast (female), unspecified site C61.0 Malignant neoplasm of prostate C49.9 Malignant neoplasm of connective & other soft tissue, NOS (sarcoma) C50.119 Malignant neoplasm, central portion of female breast Z85.46 Personal history of malignant neoplasm of prostate C67.9 Malignant neoplasm of the bladder, NOS C50.219 Malignant neoplasm, upper-inner quadrant of female breast GASTRIC CANCER C64.9 Malignant neoplasm of kidney, except pelvis C50.319 Malignant neoplasm, lower-inner quadrant of female breast DESCRIPTION C65.9 Malignant neoplasm of renal pelvis ICD10 C50.419 Malignant neoplasm, upper-outer quadrant of female breast C16.9 Malignant neoplasm of the stomach, NOS C66.9 Malignant neoplasm of ureter C50,519 Malignant neoplasm, lower-outer quadrant of female breast C17.9 Malignant neoplasm of small intestine, NOS C68.9 Malignant neoplasm of urinary system, NOS C50.619 Malignant neoplasm, axillary tail of female breast C24.9 Malignant neoplasm of biliary tract, unspecified C71.0 Malignant neoplasm of the brain C50.819 Malignant neoplasm, other specified sites of female breast Z85.068 Personal history of other malignant neoplasm of small intestine C73 Malignant neoplasm of the thyroid Personal history of malignant neoplasm of digestive organ, NOS Z85.528 Personal history of other malignant neoplasm of kidney C50.919 Malignant neoplasm, breast (female), unspecified site 785.00 PANCREATIC CANCER C50.029 Malignant neoplasm, nipple and areola of male breast Z85.53 Personal history of malignant neoplasm of renal pelvis C50.929 Malignant neoplasm, other & unspecified sites of male breast 785.54 ICD10 DESCRIPTION Personal history of malignant neoplasm of ureter C79.81 Secondary malignant neoplasm, breast C25.0 Malignant neoplasm of body of pancreas Z85.50 Personal history of malignant neoplasm of urinary tract organ, NOS D05 9 Carcinoma in situ, breast C25.1 Malignant neoplasm of tail of pancreas 785 841 Personal history of malignant neonlasm of brain C25.2 CORRESPONDING ICD-10 CODES BASED ON □ Z85.3 Personal history of malignant neoplasm, breast Malignant neoplasm of pancreatic duct **OVARIAN CANCER** C25.3 Malignant neoplasm of islets of Langerhans PATIENT'S PERSONAL AND FAMILY HISTORY DESCRIPTION C25.4 Malignant neoplasm of other specified sites of pancreas ICD10 DESCRIPTION ICD10 C25.7 Malignant neoplasm of pancreas, part unspecified C56.9 Malignant neoplasm, ovary Z85.07 Personal history of malignant neoplasm of pancreas C79.60 Secondary malignant neoplasm, ovary COLORECTAL CANCER D07.39 Carcinoma in situ, ovary N95.1 Symptomatic menopausal or female climacteric states DESCRIPTION Personal history of malignant neoplasm, ovary C18.4 Malignant neoplasm of transverse colon UTERINE CANCER C18.9 Malignant neoplasm of colon, unspecified DESCRIPTION □ C20 Malignant neoplasm of rectum ICD10 C21.0 Malignant neoplasm anus unspecified Malignant neoplasm of the uterus, part unspecified C54.9 Malignant neoplasm of the corpus uteri (uterine body) K63.5 Polyp of colon Personal history of malignant neoplasm of uterus Z85.42 Z86.010 Personal history of colonic polyps Z85.038 Personal history of other malignant neoplasm of large intestine...

INFORMED CONSENT AND STATEMENT OF MEDICAL NECESSITY — TEST REQUESTS WITHOUT A SIGNATURE WILL NOT BE PROCESSED

I have supplied information to the patient regarding genetic testing and the patient has given consent for genetic testing to be performed. I further confirm that this test is medically necessary for the diagnosis or detection of a disease, illness, impairment, symptom, syndrome or disorder, and the results will be used in the medical management and treatment decisions for the patient. I confirm that the person listed in the Ordering Physician space above is authorized by law to order the test(s) requested herein.

Medical Professional Signature	Data

INFORMED CONSENT: CANCER SCREENING

General information about genetic testing for hereditary cancer:

- Genetic disorders may be caused by mutations in the DNA sequence of a gene.
 The purpose of genetic testing is to evaluate for changes in the DNA sequence of a 2) gene and, when clinically indicated, to look for mutations. This test may help determine if I am affected with, or am at risk to someday develop, a form of hereditary cancer.
- The genes included on this test are associated with several different types of cancer and with varying levels of cancer risk.
- This test cannot identify all types of mutations, deletions, or duplications causing hereditary cancers or other genetic disorders. Specifically, this test cannot identify any genetic changes involving genes not included in the specific test(s) ordered by my health care provider.
- I understand that this test is not the only way to look for genetic abnormalities. My health care provider may recommend this test before or after ordering other genetic or laboratory tests.
- This test requires high-quality DNA. In some cases, an additional sample may be 6) needed if the volume, quality and/or condition of the initial specimen is not adequate.

What could I learn from this genetic test?

- Negative result I may learn that no genetic abnormality was identified by this test. This reduces the likelihood, but does not exclude a hereditary form of cancer
- 2) Positive result - I may learn that a genetic abnormality was identified that explains either the cause of cancer that I have and/or the risk that I have to develop cancer in the future. The type(s) of cancer for which I am at risk depends on the gene involved. These results may aid my physician in making decisions about my medical management, including but not limited to cancer screening, risk-reducing surgeries and preventive medication strategies.
- Variant of uncertain significance (VUS) I may learn that a VUS was identified by this test. This means that a genetic change (variant) was identified, but it is unknown whether the variant may cause cancer. The variant could be a normal genetic difference that does not cause medical problems, or it could be a cancer-causing abnormality. Without further information, the effects of the variant may not be known, and an inconclusive result may be reported. Testing other affected family members may be necessary to determine the significance of the variant. The laboratory will provide additional information to my healthcare provider who is ordering this testing if this variant is determined to be benign or risk-causing.

What are the limitations and risks of this genetic test?

In some cases, testing may not identify an abnormality even though a genetic abnormality may exist. This may be due to limitations in current knowledge about a gene's complete structure. It may be due to the fact that some types of genetic abnormalities causing a specific hereditary cancer have not yet been identified. I understand that

- the methods used by Advanced Molecular Diagnostics are highly accurate. However, the chance of a false positive or false negative result, due to laboratory errors incurred during any phase of testing, or due to unusual circumstances (bone marrow transplantation, blood transfusion, presence of change(s) in such a small fraction of cells that they may not be detectable (mosaicism) or incorrect reporting of family history or relationships), cannot be completely excluded.
- Accurate interpretation of the test results requires knowledge of the true biological relationships in a family. Failure to accurately disclose the biological relationships in a family may result in incorrect interpretation of results and/or inconclusive test results.
- You may be concerned about discrimination based on genetic test results. The federal government enacted the Genetic Nondiscrimination Act (GINA) of 2008 prohibiting this type of discrimination by health insurers and employers. Furthermore, genetic test results are deemed "Protected Health Information" per the Health Insurance Portability and Accountability Act (HIPAA) of 1996 which prohibits unauthorized disclosure of such information. These laws set a minimum standard of protection across the nation. Some states may have laws limiting the use of genetic information by other types of insurers as well. For additional information about these regulations, visit http://www.genome.gov/10002077.

Patient confidentiality and counseling

- To maintain confidentiality, I understand that results will be reported to the indicated healthcare provider or ordering laboratory and upon request copied to additional healthcare provider(s) indicated on the test requisition form. I understand that results may only be disclosed to others by my written consent and/ or if demanded by an order of a court of competent jurisdiction.
- Information obtained from the test may be used in scientific publications or presentations, but the identity of all individuals studied will not be revealed in such publications or presentations.
- It is recommended that I receive genetic counseling before and after having this test. Further testing or additional consultations with physicians may be necessary.

Specimen retention

Patient / Responsible Party Signature

- DNA samples are not returned to individuals or to referring physicians.
- In some cases, if further diagnostic tests are needed, a referring physician may request in writing that additional tests be performed on an existing DNA sample (additional costs apply). Additional testing will not be performed unless requested by an authorized healthcare professional.
- In some cases, de-identified DNA may be used by the laboratory for new test development and/or laboratory quality assurance purposes after all identifiers have been removed.

PAYMENT INFORMATION					
OPTION 1: PLEASE BILL MY INSURANCE (requires patient signature and enlarged copy of both sides of insurance card(s). If two cards are submitted, indicate which is primary)					
Name of Policy Holder:	DOB:	Insurance Carrier:			
Patient Relationship to Policy Holder: \Box S	elf □ Spouse □ Child □ Other	Insurance ID #:			
hereby represent that I am covered by insurance and authorize Advanced Molecular Diagnostics, LLC to furnish my designated insurance carrier, health plan, or third party administrator the information on this form and other information provided by my healthcare provider necessary for reimbursement. I authorize Advanced Molecular Diagnostics, LLC to utilize a licensed third party laboratory for test processing when deemed necessary. I authorize Plan benefits to be payable to Advanced Molecular Diagnostics, LLC in resolving insurance claim issues and if I do not assist, I may be responsible for the full test cost. I permit a copy of this authorization to be used in place insurance claim issues and if I do not assist, I may be responsible for the full test cost. I permit a copy of this authorization to be used in place			Please include a copy of both sides of all insurance card(s)		
☐ In the event that my insurance company requestions in the event that my insurance company requestions with a certified genetic					
Patient / Responsible Party Signature	Date				
OPTION 2: PATIENT PAYMENT (Patient will be contained)	cted for secure credit card information and	I to arrange payment plan)			